Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 128

1.

Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic 18F-FET PET.

Vettermann F, Suchorska B, Unterrainer M, Nelwan D, Forbrig R, Ruf V, Wenter V, Kreth FW, Herms J, Bartenstein P, Tonn JC, Albert NL.

Eur J Nucl Med Mol Imaging. 2019 Nov;46(12):2581-2589. doi: 10.1007/s00259-019-04477-3. Epub 2019 Aug 13.

PMID:
31410540
2.

Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.

Fleischmann DF, Jenn J, Corradini S, Ruf V, Herms J, Forbrig R, Unterrainer M, Thon N, Kreth FW, Belka C, Niyazi M.

Radiother Oncol. 2019 Sep;138:99-105. doi: 10.1016/j.radonc.2019.06.009. Epub 2019 Jun 25.

PMID:
31252301
3.

Photopenic defects on O-(2-[18F]-fluoroethyl)-L-tyrosine PET: clinical relevance in glioma patients.

Galldiks N, Unterrainer M, Judov N, Stoffels G, Rapp M, Lohmann P, Vettermann F, Dunkl V, Suchorska B, Tonn JC, Kreth FW, Fink GR, Bartenstein P, Langen KJ, Albert NL.

Neuro Oncol. 2019 Oct 9;21(10):1331-1338. doi: 10.1093/neuonc/noz083.

PMID:
31077276
4.

The surgical perspective in precision treatment of diffuse gliomas.

Thon N, Tonn JC, Kreth FW.

Onco Targets Ther. 2019 Feb 22;12:1497-1508. eCollection 2019. Review.

5.

Outcome after individualized stereoelectroencephalography (sEEG) implantation and navigated resection in patients with lesional and non-lesional focal epilepsy.

Thorsteinsdottir J, Vollmar C, Tonn JC, Kreth FW, Noachtar S, Peraud A.

J Neurol. 2019 Apr;266(4):910-920. doi: 10.1007/s00415-019-09213-3. Epub 2019 Jan 30.

PMID:
30701313
6.

Radiation dose and image quality in intraoperative CT (iCT) angiography of the brain with stereotactic head frames.

Forbrig R, Geyer LL, Stahl R, Thorsteinsdottir J, Schichor C, Kreth FW, Patzig M, Herzberg M, Liebig T, Dorn F, Trumm CG.

Eur Radiol. 2019 Jun;29(6):2859-2867. doi: 10.1007/s00330-018-5930-0. Epub 2019 Jan 11.

PMID:
30635759
7.

Stereotactic Internal Shunt Placement in Congenital Intracranial Cysts.

Lenski M, Biczok A, Tonn JC, Kreth FW.

World Neurosurg. 2019 Mar;123:e670-e677. doi: 10.1016/j.wneu.2018.11.250. Epub 2018 Dec 18.

PMID:
30576829
8.

Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.

Suchorska B, Schüller U, Biczok A, Lenski M, Albert NL, Giese A, Kreth FW, Ertl-Wagner B, Tonn JC, Ingrisch M.

Eur J Cancer. 2019 Jan;107:15-27. doi: 10.1016/j.ejca.2018.10.019. Epub 2018 Dec 7.

PMID:
30529899
9.

Intronic miR-744 Inhibits Glioblastoma Migration by Functionally Antagonizing Its Host Gene MAP2K4.

Hübner M, Hinske CL, Effinger D, Wu T, Thon N, Kreth FW, Kreth S.

Cancers (Basel). 2018 Oct 25;10(11). pii: E400. doi: 10.3390/cancers10110400.

10.

Voxel-wise analysis of dynamic 18F-FET PET: a novel approach for non-invasive glioma characterisation.

Vomacka L, Unterrainer M, Holzgreve A, Mille E, Gosewisch A, Brosch J, Ziegler S, Suchorska B, Kreth FW, Tonn JC, Bartenstein P, Albert NL, Böning G.

EJNMMI Res. 2018 Sep 10;8(1):91. doi: 10.1186/s13550-018-0444-y.

11.

18F-FET-PET as a biomarker for therapy response in non-contrast enhancing glioma following chemotherapy.

Suchorska B, Unterrainer M, Biczok A, Sosnova M, Forbrig R, Bartenstein P, Tonn JC, Albert NL, Kreth FW.

J Neurooncol. 2018 Sep;139(3):721-730. doi: 10.1007/s11060-018-2919-0. Epub 2018 Jun 8.

PMID:
29948765
12.

Dual-room CT with a sliding gantry for intraoperative imaging: feasibility and workflow analysis of an interdisciplinary concept.

Lenski M, Hofereiter J, Terpolilli N, Sandner T, Zausinger S, Tonn JC, Kreth FW, Schichor C.

Int J Comput Assist Radiol Surg. 2019 Feb;14(2):397-407. doi: 10.1007/s11548-018-1812-9. Epub 2018 Jun 22.

PMID:
29934791
13.

Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.

Kunz M, Albert NL, Unterrainer M, la Fougere C, Egensperger R, Schüller U, Lutz J, Kreth S, Tonn JC, Kreth FW, Thon N.

Neuro Oncol. 2019 Feb 14;21(2):274-284. doi: 10.1093/neuonc/noy098.

PMID:
29893965
14.

Correction to: Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status.

Unterrainer M, Winkelmann I, Suchorska B, Giese A, Wenter V, Kreth FW, Herms J, Bartenstein P, Tonn JC, Albert NL.

Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1078. doi: 10.1007/s00259-018-3991-6.

PMID:
29541813
15.

Biological tumour volumes of gliomas in early and standard 20-40 min 18F-FET PET images differ according to IDH mutation status.

Unterrainer M, Winkelmann I, Suchorska B, Giese A, Wenter V, Kreth FW, Herms J, Bartenstein P, Tonn JC, Albert NL.

Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1242-1249. doi: 10.1007/s00259-018-3969-4. Epub 2018 Feb 27. Erratum in: Eur J Nucl Med Mol Imaging. 2018 Mar 15;:.

PMID:
29487977
16.

Brachytherapy of Intracranial Gliomas.

Nachbichler SB, Kreth FW.

Prog Neurol Surg. 2018;31:72-86. doi: 10.1159/000467114. Epub 2018 Jan 25. Review.

PMID:
29393178
17.

The role of surgery for brain metastases from solid tumors.

Thon N, Kreth FW, Tonn JC.

Handb Clin Neurol. 2018;149:113-121. doi: 10.1016/B978-0-12-811161-1.00008-6. Review.

PMID:
29307348
18.

Cystic Craniopharyngiomas: Microsurgical or Stereotactic Treatment?

Rachinger W, Oehlschlaegel F, Kunz M, Fuetsch M, Schichor C, Thurau S, Schopohl J, Seelos K, Tonn JC, Kreth FW.

Neurosurgery. 2017 May 1;80(5):733-743. doi: 10.1227/NEU.0000000000001408.

PMID:
27973392
19.

Outcome in unresectable glioblastoma: MGMT promoter methylation makes the difference.

Thon N, Thorsteinsdottir J, Eigenbrod S, Schüller U, Lutz J, Kreth S, Belka C, Tonn JC, Niyazi M, Kreth FW.

J Neurol. 2017 Feb;264(2):350-358. doi: 10.1007/s00415-016-8355-1. Epub 2016 Dec 5.

PMID:
27921166
20.

Iodine-125 brachytherapy as upfront and salvage treatment for brain metastases : A comparative analysis.

Romagna A, Schwartz C, Egensperger R, Watson J, Tonn JC, Belka C, Kreth FW, Nachbichler SB.

Strahlenther Onkol. 2016 Nov;192(11):780-788. Epub 2016 Jun 27.

PMID:
27349709
21.

Suspected recurrence of brain metastases after focused high dose radiotherapy: can [18F]FET- PET overcome diagnostic uncertainties?

Romagna A, Unterrainer M, Schmid-Tannwald C, Brendel M, Tonn JC, Nachbichler SB, Muacevic A, Bartenstein P, Kreth FW, Albert NL.

Radiat Oncol. 2016 Oct 21;11(1):139.

22.

Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma.

Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M.

J Neurooncol. 2016 Dec;130(3):591-599. Epub 2016 Sep 6.

PMID:
27599828
23.

Comment on: the role of biopsy in the management of patients with presumed diffuse low grade glioma: a systematic review and evidence-based clinical practice guideline.

Schwartz C, Kreth FW.

J Neurooncol. 2016 May;128(1):173. doi: 10.1007/s11060-016-2086-0. Epub 2016 Feb 26. No abstract available.

PMID:
26921095
24.

Early treatment of complex located pediatric low-grade gliomas using iodine-125 brachytherapy alone or in combination with microsurgery.

Kunz M, Nachbichler SB, Ertl L, Fesl G, Egensperger R, Niyazi M, Schmid I, Tonn JC, Peraud A, Kreth FW.

Cancer Med. 2016 Mar;5(3):442-53. doi: 10.1002/cam4.605. Epub 2015 Dec 29.

25.

The role of surgery in grade II/III oligodendroglial tumors.

Thon N, Kreth FW, Tonn JC.

CNS Oncol. 2015;4(5):317-23. doi: 10.2217/cns.15.26. Epub 2015 Oct 19. Review.

26.

Outcome and toxicity profile of salvage low-dose-rate iodine-125 stereotactic brachytherapy in recurrent high-grade gliomas.

Schwartz C, Romagna A, Thon N, Niyazi M, Watson J, Belka C, Tonn JC, Kreth FW, Nachbichler SB.

Acta Neurochir (Wien). 2015 Oct;157(10):1757-64; discussion 1764. doi: 10.1007/s00701-015-2550-1. Epub 2015 Aug 23.

PMID:
26298594
27.

Biological tumor volume in 18FET-PET before radiochemotherapy correlates with survival in GBM.

Suchorska B, Jansen NL, Linn J, Kretzschmar H, Janssen H, Eigenbrod S, Simon M, Pöpperl G, Kreth FW, la Fougere C, Weller M, Tonn JC; German Glioma Network.

Neurology. 2015 Feb 17;84(7):710-9. doi: 10.1212/WNL.0000000000001262. Epub 2015 Jan 21.

28.

Prognostic significance of dynamic 18F-FET PET in newly diagnosed astrocytic high-grade glioma.

Jansen NL, Suchorska B, Wenter V, Schmid-Tannwald C, Todica A, Eigenbrod S, Niyazi M, Tonn JC, Bartenstein P, Kreth FW, la Fougère C.

J Nucl Med. 2015 Jan;56(1):9-15. doi: 10.2967/jnumed.114.144675.

29.

Dynamic 18F-FET PET in suspected WHO grade II gliomas defines distinct biological subgroups with different clinical courses.

Thon N, Kunz M, Lemke L, Jansen NL, Eigenbrod S, Kreth S, Lutz J, Egensperger R, Giese A, Herms J, Weller M, Kretzschmar H, Tonn JC, la Fougère C, Kreth FW.

Int J Cancer. 2015 May 1;136(9):2132-45. doi: 10.1002/ijc.29259. Epub 2014 Nov 3.

30.

Diffuse leukoencephalopathy with spheroids: biopsy findings and a novel mutation.

Levin J, Tiedt S, Arzberger T, Biskup S, Schuberth M, Stenglein-Krapf G, Kreth FW, Högen T, la Fougère C, Linn J, van der Knaap MS, Giese A, Kretzschmar HA, Danek A.

Clin Neurol Neurosurg. 2014 Jul;122:113-5. doi: 10.1016/j.clineuro.2014.04.022. Epub 2014 May 4. No abstract available.

PMID:
24908228
31.

Molecular stereotactic biopsy technique improves diagnostic accuracy and enables personalized treatment strategies in glioma patients.

Eigenbrod S, Trabold R, Brucker D, Erös C, Egensperger R, La Fougere C, Göbel W, Rühm A, Kretzschmar HA, Tonn JC, Herms J, Giese A, Kreth FW.

Acta Neurochir (Wien). 2014 Aug;156(8):1427-40. doi: 10.1007/s00701-014-2073-1. Epub 2014 May 3.

PMID:
24792966
32.

Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.

Flieger M, Ganswindt U, Schwarz SB, Kreth FW, Tonn JC, la Fougère C, Ertl L, Linn J, Herrlinger U, Belka C, Niyazi M.

J Neurooncol. 2014 Apr;117(2):337-45. doi: 10.1007/s11060-014-1394-5. Epub 2014 Feb 7.

PMID:
24504501
33.

Male sex as a risk factor for the clinical course of skull base chordomas.

Rachinger W, Eigenbrod S, Dützmann S, Simon M, Feigl GC, Kremenevskaja N, Kretzschmar H, Zausinger S, Kreth FW, Thon N, Tonn JC.

J Neurosurg. 2014 Jun;120(6):1313-20. doi: 10.3171/2013.11.JNS131137. Epub 2014 Jan 3.

PMID:
24405075
34.

Dynamic 18F-FET PET in newly diagnosed astrocytic low-grade glioma identifies high-risk patients.

Jansen NL, Suchorska B, Wenter V, Eigenbrod S, Schmid-Tannwald C, Zwergal A, Niyazi M, Drexler M, Bartenstein P, Schnell O, Tonn JC, Thon N, Kreth FW, la Fougère C.

J Nucl Med. 2014 Feb;55(2):198-203. doi: 10.2967/jnumed.113.122333. Epub 2013 Dec 30.

35.

Gross total but not incomplete resection of glioblastoma prolongs survival in the era of radiochemotherapy.

Kreth FW, Thon N, Simon M, Westphal M, Schackert G, Nikkhah G, Hentschel B, Reifenberger G, Pietsch T, Weller M, Tonn JC; German Glioma Network.

Ann Oncol. 2013 Dec;24(12):3117-23. doi: 10.1093/annonc/mdt388. Epub 2013 Oct 14.

36.

Personalized treatment strategies in glioblastoma: MGMT promoter methylation status.

Thon N, Kreth S, Kreth FW.

Onco Targets Ther. 2013 Sep 27;6:1363-72. doi: 10.2147/OTT.S50208. Review.

37.

Protoporphyrin IX fluorescence and photobleaching during interstitial photodynamic therapy of malignant gliomas for early treatment prognosis.

Johansson A, Faber F, Kniebühler G, Stepp H, Sroka R, Egensperger R, Beyer W, Kreth FW.

Lasers Surg Med. 2013 Apr;45(4):225-34. doi: 10.1002/lsm.22126. Epub 2013 Mar 26.

PMID:
23533060
38.

[18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma.

Jansen NL, Suchorska B, Schwarz SB, Eigenbrod S, Lutz J, Graute V, Bartenstein P, Belka C, Kreth FW, la Fougère C.

Mol Imaging. 2013 May;12(3):137-47.

PMID:
23490440
39.

In human glioblastomas transcript elongation by alternative polyadenylation and miRNA targeting is a potent mechanism of MGMT silencing.

Kreth S, Limbeck E, Hinske LC, Schütz SV, Thon N, Hoefig K, Egensperger R, Kreth FW.

Acta Neuropathol. 2013 May;125(5):671-81. doi: 10.1007/s00401-013-1081-1. Epub 2013 Jan 23.

PMID:
23340988
40.

Optical needle endoscope for safe and precise stereotactically guided biopsy sampling in neurosurgery.

Göbel W, Brucker D, Kienast Y, Johansson A, Kniebühler G, Rühm A, Eigenbrod S, Fischer S, Goetz M, Kreth FW, Ehrhardt A, Stepp H, Irion KM, Herms J.

Opt Express. 2012 Nov 19;20(24):26117-26. doi: 10.1364/OE.20.026117.

PMID:
23187467
41.

Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas.

Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, Pöpperl G, Kretzschmar HA, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C, Thon N.

Neuro Oncol. 2012 Dec;14(12):1473-80. doi: 10.1093/neuonc/nos259. Epub 2012 Oct 22.

42.

Personalized surgical therapy.

Tonn JC, Thon N, Schnell O, Kreth FW.

Ann Oncol. 2012 Sep;23 Suppl 10:x28-32.

PMID:
22987977
43.

FET-PET assessed recurrence pattern after radio-chemotherapy in newly diagnosed patients with glioblastoma is influenced by MGMT methylation status.

Niyazi M, Schnell O, Suchorska B, Schwarz SB, Ganswindt U, Geisler J, Bartenstein P, Kreth FW, Tonn JC, Eigenbrod S, Belka C, la Fougère C.

Radiother Oncol. 2012 Jul;104(1):78-82. doi: 10.1016/j.radonc.2012.04.022. Epub 2012 Jun 5.

PMID:
22673727
44.

Epigenetics in human gliomas.

Kreth S, Thon N, Kreth FW.

Cancer Lett. 2014 Jan 28;342(2):185-92. doi: 10.1016/j.canlet.2012.04.008. Epub 2012 Apr 21. Review.

PMID:
22531315
45.

MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET?

Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougère C.

Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1021-9. doi: 10.1007/s00259-012-2109-9. Epub 2012 Apr 11.

PMID:
22491781
46.

Iodine-125 brachytherapy for brain tumours--a review.

Schwarz SB, Thon N, Nikolajek K, Niyazi M, Tonn JC, Belka C, Kreth FW.

Radiat Oncol. 2012 Mar 6;7:30. doi: 10.1186/1748-717X-7-30. Review.

47.

Low-grade gliomas.

Kreth FW, Thon N, Tonn JC.

J Neurosurg. 2012 Feb;116(2):468-70; author reply 469-70. doi: 10.3171/2011.3.JNS11486. Epub 2011 Nov 25. No abstract available.

PMID:
22117182
48.

α-Internexin in the diagnosis of oligodendroglial tumors and association with 1p/19q status.

Eigenbrod S, Roeber S, Thon N, Giese A, Krieger A, Grasbon-Frodl E, Egensperger R, Tonn JC, Kreth FW, Kretzschmar HA.

J Neuropathol Exp Neurol. 2011 Nov;70(11):970-8. doi: 10.1097/NEN.0b013e3182333ef5.

PMID:
22002423
49.

Molecular imaging of gliomas with PET: opportunities and limitations.

la Fougère C, Suchorska B, Bartenstein P, Kreth FW, Tonn JC.

Neuro Oncol. 2011 Aug;13(8):806-19. doi: 10.1093/neuonc/nor054. Epub 2011 Jul 13. Review.

50.

IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival.

Thon N, Eigenbrod S, Kreth S, Lutz J, Tonn JC, Kretzschmar H, Peraud A, Kreth FW.

Cancer. 2012 Jan 15;118(2):452-60. doi: 10.1002/cncr.26298. Epub 2011 Jun 29.

Supplemental Content

Loading ...
Support Center